Sign up
Pharma Capital

Summit Therapeutics boosted by new DMD drug analysis

It comes as the company and its investors await full results in the third quarter
pharmaceutical research
Summit shares climbed 5.97% to trade at 204p.

Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) has highlighted new analysis from the group’s Phase Two clinical trial, for its potential treatment for Duchenne muscular dystrophy (DMD).

The company, in a statement, said the new analysis showed a high correlation between reductions in developmental myosin, a biomarker of muscle damage, and reductions in muscle inflammation in patients after 24 weeks of ezutromid treatment.

READ: Summit Therapeutics boosted by new DMD drug analysis

It added that the findings underpin existing evidence that Summit’s drug, ezutromid, is reducing the severity of DMD.

"The correlation observed between decreases in developmental myosin, a biomarker of muscle damage, and decreases in muscle fibre inflammation, is highly encouraging, and we believe further supports that ezutromid is breaking the DMD disease cycle of muscle damage and repair," said Dr David Roblin, Summit chief medical officer.

“We look forward to reporting the full results of this trial, expected in the third quarter of 2018."

Summit shares climbed 11.5p or 5.97% to trade at 204p.

Why Invest In Summit Therapeutics PLC? Read More Here

Register here to be notified of future SUMM Company articles
View full SUMM profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.